Erasca Quarterly Cash Flow Statement
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.03+0.57 (+3.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Erasca free cash flow
In the quarter ended Jun 30, 2026, Erasca generated -$27.3 million of operating cash flow and spent $8,000 on capital expenditures. That left free cash flow of -$27.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Erasca cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -44.08M | -183.44M | -29.09M | -30.61M | -33.88M | -30.97M | -32.23M | -31.20M | -63.20M | -35.02M | -29.70M | -30.36M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 716.00K | 723.00K | 743.00K | 755.00K | 787.00K | 822.00K | 832.00K | 842.00K | 1.10M | 998.00K | 942.00K | 941.00K |
| Stock-Based Compensation | 9.61M | 8.46M | 5.82M | 5.96M | 6.40M | 6.71M | 6.31M | 6.64M | 7.18M | 6.85M | 6.14M | 6.24M |
| Change in Working Capital | -212.00K | 1.18M | -2.05M | 1.37M | -599.00K | 1.79M | -1.94M | 482.00K | -710.00K | 633.00K | -1.66M | 1.03M |
| Operating Cash Flow | -27.27M | -27.38M | -21.71M | -21.66M | -20.53M | -31.55M | -24.56M | -22.42M | -29.18M | -33.25M | -24.79M | -24.12M |
| Capital Expenditures | -8.00K | -36.00K | -9.00K | -6.00K | -30.00K | -83.00K | 0 | -5.00K | -13.00K | -42.00K | -82.00K | -240.00K |
| Investing Cash Flow | 19.49M | -243.83M | 24.71M | 25.70M | 15.74M | 34.27M | 22.62M | -102.59M | -86.61M | 9.97M | 4.54M | -1.81M |
| Financing Cash Flow | 3.06M | 244.66M | 575.00K | 41.00K | 447.00K | 33.00K | 801.00K | 21.10M | 211.87M | 6.93M | 456.00K | 7.00K |
| Net Change in Cash | -4.71M | -26.55M | 3.58M | 4.09M | -4.34M | 2.74M | -1.15M | -103.92M | 96.08M | -16.35M | -19.79M | -25.93M |
| Free Cash Flow | -27.28M | -27.42M | -21.72M | -21.66M | -20.56M | -31.64M | -24.56M | -22.42M | -29.20M | -33.29M | -24.87M | -24.36M |
This table shows 12 quarterly periods of Erasca's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ERAS's reporting calendar. What is a cash flow statement?